Page 274 - 2021_02-Haematologica-web

588
Letters to the Editor
FKBP-FK506 complexes. Cell. 1991;66(4):807-815.
9. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K.
Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol. 1990;145(5):1303- 1310.
10. Russo A, Oliveira G, Berglund S, et al. NK cell recovery after hap- loidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247-262.
11. McCurdy SR, Luznik L. Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Semin Hematol. 2019;56(3):221- 226.
12. Pérez-Martínez A, González-Vicent M, Valentín J, et al. Early evalu- ation of immune reconstitution following allogeneic CD3/CD19- depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplant. 2012;47(11):1419-1427.
13.Touma W, Brunstein CG, Cao Q, et al. Dendritic cell recovery impacts outcomes after umbilical cord blood and sibling donor trans- plantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(11):1925-1931.
14.
Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T- cell-replete haploidentical donor transplantation using post-trans- plant cyclophosphamide. J Clin Oncol. 2017;35(26):3002-3009.
haematologica | 2021; 106(2)